Business Wire

Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020


Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from FLEX, the large-scale, prospective, observational breast cancer study, has been selected for presentation in six posters during the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The posters, being presented at different sessions throughout SABCS 2020, focus on underrepresented or underserved populations or types of breast cancer.

“FLEX could be one of the most valuable, impactful, flexible, and inclusive studies in breast cancer research to date,” said Laura Lee, M.D., Surgical Oncology Specialist at Desert Comprehensive Breast Center at Desert Regional Medical Center, and first author of the FLEX update poster. “These data reveal that tumor heterogeneity goes beyond ethnicities and underscores the importance of gene expression analysis as a tool for bringing those differences to light. We are enrolling patients representing all of the clinical and genomic subtypes from a broad spectrum of community and academic sites. As researchers, we are excited by the opportunity to access this real-world data set where we can ask meaningful clinical questions and then see what the data tell us.”

Highlights from the FLEX data are as follows:

  • [OT12-01] The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer outlines updates from the FLEX study, a registry intended to enable the discovery of novel genomic profiles to improve precision in the management of breast cancer. With purposefully-wide inclusion criteria, the registry aims to enable researchers to investigate the differences and trends between breast cancer subgroups and allow focus on smaller, more diverse patient populations, which have traditionally been challenging to recruit in sufficient numbers for clinical trials.
  • [PS7-69] Molecular profiles and clinical-pathologic features of Asian early-stage breast cancer patients assesses the clinical, pathological and molecular profiles from self-reported Asian breast cancer patients (AS), in comparison with age-matched Caucasian (CA) and African American patients (AA), to evaluate the influence of Asian ancestry on differential gene expression in breast tumors. The analysis revealed different gene set enrichment patterns in tumors of AS compared with CA and AA, which may contribute to differential clinical outcomes and highlights the importance of including patients of Asian ancestry in genomic breast cancer research. Additionally, the poster found more differentially-expressed genes in MammaPrint High Risk tumors between AS and AA patients than between AS and CA patients, reinforcing the need for additional research to evaluate the influence of ancestry on differential gene expression in breast tumors.
  • [PS14-11] Differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients compares the under-researched population of male breast cancer patients (MaBC) to that of female breast cancer patients (FBC) to determine whether significant molecular biological differences exist between the two groups. Utilizing the MammaPrint and BluePrint assays, the analysis suggests that distinct biological pathways between the two groups indicate an upregulation of estrogen response and MTORC1 signaling in MaBC compared to FBC, and warrants further investigation to assess clinical outcomes.
  • [PS7-68] Racial disparities within Basal-type breast cancer: clinical and molecular features of African American (AA) and Caucasian (CA) obese patients investigates differential gene expression between two ethnic groups with clinically-matched comorbidities, in this case diabetes and obesity, who have been diagnosed with Basal-type breast cancer. The goal is to determine the influence metabolic factors or patient ancestry may have on outcomes as these data mature. Currently, the analysis suggests that there are further disparities in AA and CA patients beyond those attributable to clinical and social factors, which may help identify novel treatment approaches in the future.
  • [PS18-03] Differential gene expression in Luminal-Type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification assesses differential gene expression between invasive lobular carcinomas (ILC) and invasive ductal carcinomas (IDC) in a large, age-matched patient subset using MammaPrint and BluePrint to stratify those populations. The analysis suggests that when evaluated by MammaPrint, about one-third of ILCs were classified as MammaPrint High Risk, displaying heterogeneity in High Risk tumors and MammaPrint’s ability to predict unfavorable survival outcomes for patients with this type of tumor. The study results underscore the ability of FLEX to enroll smaller patient populations on a larger scale, enabling further investigation and the opportunity to provide targets for treatment optimization for those patients.
  • [PS18-05] Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers assesses triple negative breast cancers (TNBC) to understand the relationship between gene expression signatures provided by BluePrint and immunohistochemistry-defined TNBC. The analysis suggests that BluePrint enables further stratification of TNBC tumors, moving this type of cancer into different subgroups and shedding new light on TNBC tumor heterogeneity that may one day impact treatment planning.

“TNBC has long been a difficult diagnosis for both patients and physicians because of its aggressive nature. Very often, there is no time and no room for trial and error in the treatment decision-making process so there is a lot of pressure to get things right,” said Virginia Kaklamani, M.D., Co-director of SABCS, leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, Professor of Medicine in the Division of Hematology/Oncology at UT Health San Antonio, and first author on the poster focusing on TNBC tumors. “By leveraging BluePrint for the evaluation and stratification of TNBC tumors, we hope to be able to tease out the differences in this challenging type of cancer – which can sometimes include more than one activated genomic pathway – to determine where and when to hit it hardest for the benefit of our patients.”

These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit

Contact information

Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Maxon Announces the Acquisition of Japanese Distributor Business19.1.2021 16:50:00 CETPress release

Today, Maxon announced it has completed the transaction to acquire the business segment of its Japanese distributor that services Maxon’s community and business concerns, and the formation of the first official office in Japan: Maxon Computer KK. For the last ten years, Maxon’s Japan Representative office in Tokyo, TMS Corp, has been well-known amongst the Maxon community. The establishment of Maxon Computer KK seeks to deepen this connection and show Maxon’s ongoing commitment to the Japanese market. Maxon have also announced that TMS Corp founder, Manfred Flick, has been appointed as the Regional Director of this new subsidiary. In addition, his entire motivated team will be part of the Maxon family. This press release features multimedia. View the full release here: Establishment of Maxon Computer KK to Strengthen Relationship with the Japanese Market and Provide Direct Support for the Cinema 4D, Red Giant and Redshift Artist

Andersen Global Enters Malawi19.1.2021 15:30:00 CETPress release

Andersen Global establishes a foothold in the Malawi market through a Collaboration Agreement with Knight & Knight, bolstering its platform on the African continent and adding additional coverage in the eastern region. Established in 2003, Knight & Knight is a full-service law firm specializing in all facets of business law with capabilities in banking and finance, litigation, intellectual property, commercial, real estate, employment, mergers and acquisitions, and regulatory matters. With two partners and six professionals, the firm serves individuals and organizations of various sizes, representing a large number of businesses across the country as well as transactional entities, multinational corporations, banking and financial institutions, public sector undertakings, various ministries, state and central government authorities, and nongovernmental organizations. “At the core of our business, our philosophy has always been to offer best-in-class services designed to meet our client

Pitney Bowes Appoints Ana Maria Chadwick as Executive Vice President and Chief Financial Officer19.1.2021 15:00:00 CETPress release

Pitney Bowes (NYSE: PBI), a global technology company that provides commerce solutions in the areas of ecommerce, shipping, mailing and financial services, today announced that Ana Maria Chadwick has been appointed Executive Vice President and Chief Financial Officer, effective January 29, 2021. This press release features multimedia. View the full release here: Pitney Bowes Appoints Ana Chadwick as Executive Vice President and CFO (Photo: Business Wire) Ms. Chadwick joins Pitney Bowes from GE Capital where she held several executive positions. Her responsibilities included both operational and financial positions, along with strong transformational and financial services experience. Most recently, Ms. Chadwick was President and CEO of GE Capital Global Legacy Solutions. Previously, she was Controller of GE Capital Americas and Chief Financial Officer at GE Capital Energy Financial Services. Ms. Chadwick also has substantial glo

Globality, the World’s First Smart Sourcing Platform Powered by AI, Raises $138.3 Million of Series E Funding From Sienna Capital, a Wholly Owned Subsidiary of Groupe Bruxelles Lambert, and the SoftBank Vision Fund19.1.2021 14:00:00 CETPress release

Globality, the leading AI-powered digital solution for sourcing strategic services, announced today it has closed an investment of $138.3 million from Sienna Capital, a wholly owned subsidiary of Groupe Bruxelles Lambert (GBL), and the SoftBank Vision Fund. This new investment brings Globality’s total funding to $310.3 million since being founded five years ago. As part of the investment, Colin Hall, vice-chairman of Sienna Capital, will join the company’s board of directors. This press release features multimedia. View the full release here: Joel Hyatt, Co-Founder, Chairman, and CEO of Globality (Photo: Business Wire) The Series E round of funding enables Globality to fuel its rapid growth by investing in additional AI technology capabilities. It also directly supports the company’s efforts to increase its global scale and capacity; add world-class talent to the engineering, product and client teams; and expand its marketing an

Zynga Launches Harry Potter: Puzzles & Spells in South Korea19.1.2021 14:00:00 CETPress release

Zynga Inc. (Nasdaq: ZNGA): This press release features multimedia. View the full release here: Zynga Launches Harry Potter: Puzzles & Spells in South Korea (Graphic: Business Wire) WHO: Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced that Harry Potter: Puzzles & Spells has launched in South Korea. Officially licensed from Warner Bros. Games and published under the Portkey Games label, this award-winning mobile game has begun rolling out to players in South Korea, fully localized in Korean. WHAT: Recipient of a Google Play 2020 Award for Best Casual Game and Apple App Store Editors’ Choice Award, Harry Potter: Puzzles & Spells is now available for free download on the App Store and Google Play in South Korea. Players in this region can access all current and previously released content, featuring more than 1,000 magic-infused Match-3 puzzles inspired by the story of Harry Potter and the wizardin

PPRO Raises $180 Million for the Next Era of Local Payments Infrastructure, Is Now Valued Over $1 Billion19.1.2021 14:00:00 CETPress release

PPRO, the global provider of local payments infrastructure, today announced over US $180 million in new investment. Investors include Eurazeo Growth, Sprints Capital, and Wellington Management. This news comes just six months after the company raised US $50 million from Sprints Capital as well as Citi Ventures and HPE Growth. PPRO’s valuation is now over US $1 billion. PPRO has established itself as the most trusted infrastructure provider in the cross-border payments space, powering international growth for payment service providers and platforms such as Citi, Elavon, Mastercard Payment Gateway Services, Mollie, PayPal, and Worldpay. PPRO’s local payments platform and expert services help its customers get the industry’s best conversion rates in markets around the world by allowing online shoppers to pay with their preferred payment method. PPRO’s valuation is underscored by its rapid growth last year. The company doubled its year-on-year transaction volumes in the fourth quarter of 2

ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 With Cyclotron Produced 68 Ga Utilizing the QUANTM Irradiation System™ and Solid Targets19.1.2021 14:00:00 CETPress release

ARTMS Inc. (ARTMS) and Isotopia MolecularImaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system. This press release features multimedia. View the full release here: The specially designed Prostate-Specific Membrane Antigen (PSMA) kit for the preparation of 68Ga-PSMA-11 (a radiopharmaceutical targeting PSMA for the imaging of prostate cancer using Positron Emission Tomography (PET)) was radiolabeled with high activity cyclotron produced 68Ga following irradiation times of less than two hours. The Isotopia kit was radiolabeled with between 500 mCi and just over 2900 mCi of 68Ga following multiple successful 68Ga production runs utilizing the QIS™ and ARTMS’ high performance 68Zn solid targets. The resultant product demonst